Latest Close
$2.38
News
ACTU
Actuate Therapeutics, Inc. News
This news view pulls recent coverage and headlines tied to ACTU.
1y Change
-$7.95 (-76.96%)
Market Cap
$56,943,532.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
GlobeNewswire • May 11, 2026
Read articleActuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
GlobeNewswire • May 6, 2026
Read articleB. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating
MT Newswires • Apr 15, 2026
Read articleActuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
GlobeNewswire • Apr 14, 2026
Read articleActuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
ACCESS Newswire • Mar 24, 2026
Read articleActuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
GlobeNewswire • Mar 9, 2026
Read article